Palvella Therapeutics (PVLA) Interest Expenses (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Interest Expenses data on file, last reported at $314.3 million in Q1 2026.

• On a quarterly basis, Interest Expenses rose 714.25% year-over-year to $314.3 million in Q1 2026; TTM through Mar 2026 was $314.3 million, a 714.25% increase from a year earlier, with the FY2025 full-year figure at $131.2 million, up 40.62% from the prior year.
• Interest Expenses for Q1 2026 stood at $314.3 million, up from $38.6 million in the prior quarter.
• Over the last five years, Interest Expenses for PVLA reached as high as $314.3 million in Q1 2026 and fell as low as -$1.6 million in Q4 2023.
• Historically, Interest Expenses has averaged $27.4 million across 5 years, with a median of $500000.0 in 2022.
• Across the five-year window, Interest Expenses slumped 300.0% in 2023 and soared 714.25% in 2026, its largest moves.
• Year by year, Interest Expenses stood at $800000.0 in 2022, then slumped by 300.0% to -$1.6 million in 2023, then soared by 111.31% to $181000.0 in 2024, then jumped by 21225.97% to $38.6 million in 2025, then surged by 714.25% to $314.3 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $314.3 million in Q1 2026, $38.6 million in Q1 2025, and $181000.0 in Q4 2024.